103 patents
Page 2 of 6
Utility
Tangential viral filtration
22 Nov 22
Viral filters include a filter member featuring a first surface and a second surface and having a thickness extending between the first and second surfaces in a first direction, and a plurality of channels formed in the filter member, each of the channels having a channel axis, where during use, a solution carrying a viral load flows in a direction parallel to the first surface, and at least a portion of the viral load enters the membrane through the first surface and propagates in the first direction, and where for at least 50% of the channels in the filter member, the channel axis is oriented at an angle of between 5 degrees and 85 degrees relative to the first direction.
Tarl Vetter, Kevin Brower
Filed: 11 Mar 20
Utility
FGFR3 antibodies and methods of use
22 Nov 22
Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided.
Yves Sabbagh, Yangde Chen, William Brondyk, Huawei Qiu, Sunghae Park, Ronnie Wei, Yu Qiu, Yanfeng Zhou, Cendrine Lemoine, HyunSuk Cho
Filed: 20 Aug 21
Utility
ixz5jyktr5xu2j26d3nwjobncrik7lt
4 Oct 22
Hanlan Liu, Chris Willis, Renu Bhardwaj, Jianmei Kochling, Craig Siegel
Filed: 24 Nov 10
Utility
2lz47xb71g7bhugs4j27rqu60nkhesmgdzv4s3
13 Sep 22
Viral filters include a filter member featuring a first surface and a second surface and having a thickness extending between the first and second surfaces in a first direction, and a plurality of channels formed in the filter member, each of the channels having a channel axis, where during use, a solution carrying a viral load flows in a direction parallel to the first surface, and at least a portion of the viral load enters the membrane through the first surface and propagates in the first direction, and where for at least 50% of the channels in the filter member, the channel axis is oriented at an angle of between 5 degrees and 85 degrees relative to the first direction.
Tarl Vetter, Kevin Brower
Filed: 7 Dec 21
Utility
6hm1iktb7c1ilriqdmnqli rcfvh26qm84l54o
6 Sep 22
The disclosure provides a filtration system for a cell culture apparatus and a method of cell culture.
Jiuyi Lu, Jason Walther, Jonathan Wang, Kevin Victor Chen
Filed: 11 Nov 21
Utility
7fch06nix5en6 cl1y40bdz6bw70kszwessbzaffpz63
9 Aug 22
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease.
John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
Filed: 25 Sep 20
Utility
iqat8gal8lv0p6zi7c6x1nun7p9v2173fjnm2ngo 4fr8
19 Jul 22
Provided herein are methods of predicting the effect of a concentration of a sensitizer on cell viability in a production bioreactor, methods of improving cell viability in a production bioreactor, methods of predicting cell viability in a production bioreactor, and methods for culturing a cell in a production bioreactor.
Jonathan Wang, Neha Shah, Jason Walther, Jiuyi Lu, Timothy Johnson, Yukun Ren, Jean McLarty
Filed: 15 Mar 19
Utility
mif50wl4qfcdf1yve2iq5i1ki9eweoazz
10 May 22
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Julie Bird
Filed: 3 Mar 16
Utility
mqyu4vfigaq5464chb4lveeuekpi199agu6jm37cve 8k93v4uzfov
10 May 22
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 30 Oct 19
Utility
0ynrjk9xginz5io29tf27uzvcpb2q4qy5gliddo8ktc4z019zfxh99y3sg
19 Apr 22
Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Filed: 21 Dec 15
Utility
0jc 6jnenvvkhys0r2igps34op8wn2qs1qlomd7e2yaj74w
22 Mar 22
Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI.
Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
Filed: 24 Sep 19
Utility
myz6lfr1jdti6yv5mufyqfup6gblcdpavm342wv8el
15 Mar 22
John L. Kane, Jr., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Wai-Kwok Shum, Linli Wei
Filed: 19 Jul 16
Utility
2djuynl awcpjch5vnhbqkcrv6ldhof0zdw2oyy5jw3r49a8b72
8 Mar 22
Polydiallylamine copolymers are copolymers comprising monomers of polydiallylamine and either polyvinlyamine or polyallylamine.
Pradeep K. Dhal, Robert J. Miller, Steven C. Polomoscanik, Philip Just Larsen, Thomas Huebschle, Thorsten Schmidt, Ian Davison, Peter D. McDonnell, Chinyere Agbugba
Filed: 16 Dec 15
Utility
rkocu7g8uu29hr3exbm2vjpcns8yuqc74oings26v4yd78qazxv ebq36xmn
1 Mar 22
Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described.
Guang Qu, John Fraser Wright
Filed: 12 Aug 19
Utility
ipzxl t5llzuzfwerzkjpupmxt81zbgoxpumvmu3
22 Feb 22
Neurological diseases, including lysosomal storage diseases, can be successfully treated using intraventricular delivery of the therapeutic agents to bypass the blood-brain barrier.
James C. Dodge, Marco A. Passini, Lamya S. Shihabuddin, Seng H. Cheng
Filed: 21 Feb 19
Utility
zefwnfifl5ju3clnlrnooq4wjb1wpq7t40345vndzal3ucs6zwd
8 Feb 22
Provided herein are humanized anti-factor Bb antibodies, methods of producing the antibodies and methods of using the antibodies.
Graham Parry, Stephen Moore, Michael Storek, Nina C. Leksa
Filed: 19 Apr 21
Utility
9dg2mf51ylswr2 2difmu6
1 Feb 22
Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
Carl A. Beigie
Filed: 20 Dec 18
Utility
in8qyc xe3npd5ttz8bhunvwla9spvqcz8pmmcxcca
25 Jan 22
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 1 Jul 19
Utility
ymwjwfwme14ixr6lktl36va l62rze
4 Jan 22
Methods and kits for detecting antibodies (e.g., anti-drug antibodies).
Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
Filed: 8 Aug 17
Utility
x0ok327roy1xatiz8ex1lh3yp17g5s85wvezomii9p
28 Dec 21
Provided herein are recombinant glycoproteins (e.g., recombinant human α-galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins.
Karen Lee, Christopher Hwang, Christine DeMaria
Filed: 22 Oct 14